InMed Pharmaceuticals (INM) Free Cash Flow Growth (1y) (2020 - 2026)
InMed Pharmaceuticals (INM) Free Cash Flow Growth (1y) (2020 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.89 Bn | 42.93 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.33 Bn | 2.15 Bn | 134.35% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 17.21% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -37.45% |
| 5 | United Therapeutics | 22.15 Bn | 19.48 Bn | 683.80 Mn | 58.76% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 97.24% |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn | 43.69% |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 35.56% |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | - |
| 10 | InMed Pharmaceuticals | 6.38 Mn | 1.14 Mn | - | -2.15% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.15% |
| Dec 31, 2025 | 5.03% |
| Sep 30, 2025 | 12.00% |
| Jun 30, 2025 | -72.81% |
| Mar 31, 2025 | 14.83% |
| Dec 31, 2024 | -35.52% |
| Sep 30, 2024 | 15.86% |
| Jun 30, 2024 | -24.98% |
| Mar 31, 2024 | -17.62% |
| Dec 31, 2023 | 31.95% |
| Sep 30, 2023 | 3.51% |
| Jun 30, 2023 | 79.99% |
| Mar 31, 2023 | 69.02% |
| Dec 31, 2022 | 17.23% |
| Sep 30, 2022 | 22.52% |
| Jun 30, 2022 | -106.42% |
| Mar 31, 2022 | -15.97% |
| Dec 31, 2021 | -81.95% |
| Sep 30, 2021 | -109.58% |
| Jun 30, 2021 | -42.64% |